Trevi Therapeutics, Inc. Stock-Based Compensation
Trevi Therapeutics, Inc. (TRVI) reported Stock-Based Compensation of $3.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Trevi Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.27M, a 136.42% increase year-over-year.
- Trevi Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.19M, a 81.37% increase year-over-year.
- Trevi Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.35M, a 47.22% increase year-over-year.
- Trevi Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.24M, a 51.22% increase year-over-year.
- Trevi Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $5.18M, a 44.51% increase from fiscal 2024.
- Trevi Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $3.59M, a 59.68% increase from fiscal 2023.
- Trevi Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.25M, a 3.44% decline from fiscal 2022.
- Trevi Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $2.33M, a 8.49% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.27M 10-Q · filed 2026-08-06 | $5.46M 10-Q · filed 2026-08-06 | $6.81M derived: sum of 3 quarters · filed 2026-08-06 | $8.06M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $2.19M 10-Q · filed 2026-05-05 | $3.54M derived: sum of 2 quarters · filed 2026-05-05 | $4.78M derived: sum of 3 quarters · filed 2026-05-05 | $6.17M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.59M derived: sum of 2 quarters · filed 2026-03-17 | $3.98M derived: sum of 3 quarters · filed 2026-08-06 | $5.18M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $1.24M 10-Q · filed 2025-11-13 | $2.63M derived: sum of 2 quarters · filed 2026-08-06 | $3.83M 10-Q · filed 2025-11-13 | $4.75M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.38M 10-Q · filed 2026-08-06 | $2.59M 10-Q · filed 2026-08-06 | $3.51M derived: sum of 3 quarters · filed 2026-08-06 | $4.33M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $1.21M 10-Q · filed 2026-05-05 | $2.13M derived: sum of 2 quarters · filed 2026-05-05 | $2.95M derived: sum of 3 quarters · filed 2026-05-05 | $4.07M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $917.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.74M derived: sum of 2 quarters · filed 2026-03-17 | $2.87M derived: sum of 3 quarters · filed 2026-03-17 | $3.59M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $822.00K 10-Q · filed 2025-11-13 | $1.95M derived: sum of 2 quarters · filed 2025-11-13 | $2.67M 10-Q · filed 2025-11-13 | $3.21M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.13M 10-Q · filed 2025-08-07 | $1.85M 10-Q · filed 2025-08-07 | $2.38M derived: sum of 3 quarters · filed 2025-08-07 | $2.91M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $723.00K 10-Q · filed 2025-05-08 | $1.26M derived: sum of 2 quarters · filed 2025-05-08 | $1.79M derived: sum of 3 quarters · filed 2025-05-08 | $2.32M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $534.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.06M derived: sum of 2 quarters · filed 2025-03-18 | $1.59M derived: sum of 3 quarters · filed 2025-03-18 | $2.25M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $530.00K 10-Q · filed 2023-11-09 | $1.06M derived: sum of 2 quarters · filed 2024-11-06 | $1.71M 10-Q · filed 2024-11-06 | $2.14M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $530.00K 10-Q · filed 2024-11-06 | $606.00K 10-Q · filed 2023-08-10 | $1.18M 10-Q · filed 2024-08-08 | $1.61M derived: sum of 3 quarters · filed 2024-11-06 | $2.18M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-03-31 | $578.00K 10-Q · filed 2024-05-07 | $1.08M derived: sum of 2 quarters · filed 2024-05-07 | $1.65M derived: sum of 3 quarters · filed 2024-05-07 | $2.17M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $501.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $1.07M derived: sum of 2 quarters · filed 2024-03-20 | $1.59M derived: sum of 3 quarters · filed 2024-03-20 | $2.33M 10-K · filed 2024-03-20 | |
| 2022-09-30 | $569.00K 10-Q · filed 2023-11-09 | $1.09M derived: sum of 2 quarters · filed 2023-11-09 | $1.83M 10-Q · filed 2023-11-09 | $2.37M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $520.00K 10-Q · filed 2023-08-10 | $1.26M 10-Q · filed 2023-08-10 | $1.80M derived: sum of 3 quarters · filed 2023-08-10 | $2.34M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $737.00K 10-Q · filed 2023-05-11 | $1.28M derived: sum of 2 quarters · filed 2023-05-11 | $1.82M derived: sum of 3 quarters · filed 2023-05-11 | $2.56M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $540.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.08M derived: sum of 2 quarters · filed 2023-03-16 | $1.82M derived: sum of 3 quarters · filed 2023-03-16 | $2.54M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $540.00K 10-Q · filed 2022-11-10 | $1.28M derived: sum of 2 quarters · filed 2022-11-10 | $2.00M 10-Q · filed 2022-11-10 | $2.51M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $745.00K 10-Q · filed 2022-08-11 | $1.46M 10-Q · filed 2022-08-11 | $1.97M derived: sum of 3 quarters · filed 2022-08-11 | $2.56M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $718.00K 10-Q · filed 2022-05-12 | $1.23M derived: sum of 2 quarters · filed 2022-05-12 | $1.82M derived: sum of 3 quarters · filed 2022-05-12 | $2.40M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.10M derived: sum of 2 quarters · filed 2022-03-17 | $1.69M derived: sum of 3 quarters · filed 2022-03-17 | $2.42M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $588.00K 10-Q · filed 2021-11-10 | $1.18M derived: sum of 2 quarters · filed 2021-11-10 | $1.91M 10-Q · filed 2021-11-10 | $2.28M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $589.00K 10-Q · filed 2021-08-12 | $1.32M 10-Q · filed 2021-08-12 | $1.69M derived: sum of 3 quarters · filed 2021-08-12 | $2.06M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $730.00K 10-Q · filed 2021-05-13 | $1.10M derived: sum of 2 quarters · filed 2021-05-13 | $1.47M derived: sum of 3 quarters · filed 2021-05-13 | $1.71M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $373.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $744.00K derived: sum of 2 quarters · filed 2021-03-25 | $981.00K derived: sum of 3 quarters · filed 2021-03-25 | $1.13M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $371.00K 10-Q · filed 2020-11-12 | $608.00K derived: sum of 2 quarters · filed 2020-11-12 | $754.00K 10-Q · filed 2020-11-12 | $939.00K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $237.00K 10-Q · filed 2020-08-13 | $383.00K 10-Q · filed 2020-08-13 | $568.00K derived: sum of 3 quarters · filed 2020-08-13 | $689.00K derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | $146.00K 10-Q · filed 2020-05-07 | $331.00K derived: sum of 2 quarters · filed 2020-05-07 | $452.00K derived: sum of 3 quarters · filed 2020-05-07 | $554.00K derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $306.00K derived: sum of 2 quarters · filed 2020-03-16 | $408.00K derived: sum of 3 quarters · filed 2020-03-16 | $496.00K 10-K · filed 2020-03-16 | |
| 2018-09-30 | $121.00K 10-Q · filed 2019-11-14 | $223.00K derived: sum of 2 quarters · filed 2019-11-14 | $311.00K 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $102.00K 10-Q · filed 2019-08-12 | $190.00K 10-Q · filed 2019-08-12 | |||
| 2018-03-31 | $88.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |